SIRT1 activator and its effect on the progression of atherosclerosis

Abstract

Atherosclerosis is the leading cause of cardiovascular disease (CVD) and the leading cause of death worldwide.
Hyperlipidemia and related lipid metabolism disorders are the main risk factors associated with the progression of
atherosclerosis. Sirtuins (SIRT1-SIRT7) are a family of NAD+ dependent deacetylases that catalyze the deacetylation of
histones and non-histone substrates. Among Sirtuins, Sirtuin 1 (SIRT1) has been intensively studied due to its extensive
regulation of life span and cell metabolism. Recently accumulated evidence indicates that the genetic and pharmacological
activation of SIRT1 has a broad preventive effect on atherosclerosis. The discovery of SIRT1 activating compounds (STAC,
SIRT1720, resveratrol, SRT3025, E1231, etc.) is feasible and is becoming a new treatment strategy for the treatment of
atherosclerosis and related cardiovascular diseases (a major fatal senile disease) .